Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia

McEvoy, Joseph P.; Gandhi, Sanjay; Rizio, Avery A.; Maher, Stephen; Kosinski, Mark; Bjørner, Jakob Bue; Carroll, Benjamin

doi:10.1007/s11136-019-02269-8

Cited by 37 publications

(33 citation statements)

References 15 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Social withdrawal and social isolation are increased in patients with schizophrenia or mood disorders who have antipsychotic-induced TD. 29 , 32 These types of negative social effects of TD are experienced by both patients and caregivers. For example, social isolation has been reported by 72.7% of the patients with TD and 18.2% of the caregivers, making it among the most commonly reported negative impacts of TD.…”

Section: Resultsmentioning

confidence: 99%

“… 10 As a result, many patients with TD report feeling embarrassed by their medical condition (eg, feeling like people are staring at them in public places). 10 , 29 , 31 , 39 Many patients and caregivers describe emotional and social impacts of TD as the most debilitating features of this disease. 29 For example, in a series of qualitative interviews, Farber and colleagues 16 found that unwanted attention related to TD was the most common negative effect of disease, reported by 90.9% of the patients and 45.5% of the caregivers In another study, 75.5% of the patients with TD reported feelings of self-consciousness or embarrassment related to their involuntary movements.…”

Section: Resultsmentioning

confidence: 99%

“…TD has been associated with decreased quality of life, increased hospitalizations, speech and eating difficulties, cognitive dysfunction, decreased employment, social withdrawal, stigmatization, amplified emotional distress, and increased psychopathology in the underlying psychiatric disorder when patients with TD are compared with non-TD counterparts. 2,11,12,[29][30][31] Although causality has not been established, and TD may be a marker of more severe illness for some patients, these potential negative effects underscore the importance of assessing TD and its impact.…”

Section: Importance Of Assessing the Impact Of Tdmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations

Jackson¹,

Brams²,

Citrome³

et al. 2021

NDT

View full text Add to dashboard Cite

Purpose: Tardive dyskinesia (TD) is a hyperkinetic movement disorder in which patients experience abnormal involuntary movements that can have profound negative impacts on physical, cognitive, and psychosocial functioning. Use of measures to assess the functional impact of TD in routine clinical practice is lacking. To address this gap, an advisory panel of experts in psychiatry and movement disorder neurology was convened to develop consensus recommendations on assessment of the impact of TD on patients' functioning that can be used in clinical practice. Methods: An advisory panel provided recommendations using an iterative process, beginning with a narrative literature review regarding current practices for assessing the impact of TD in clinical settings. A detailed summary was generated, and the advisory panel provided comments about the content and answered questions about assessing TD impact in clinical practice. The panelists' responses were discussed during a virtual meeting held on August 28, 2020. A second meeting on September 25, 2020, focused on developing and refining recommendations for assessment of the impact of TD in clinical practice. At the conclusion of the second meeting, general consensus was reached on all recommendation statements. Results: As part of routine clinical practice, it is imperative to assess the impact of TD on the patient's life to help guide treatment decisions. Key domains for assessing the overall impact of TD include social, physical, vocational, and psychological functioning and the impact of TD on the underlying psychiatric disorder. Assessment of TD impact should be performed at every patient visit. Impact assessments should include consultation with patients, caregivers, and family members. Shared decision-making to initiate TD treatment should consider impact. Conclusion:The impact of TD should be assessed routinely, including the key domains of social, physical, vocational, and psychological functioning and the impact of TD on the underlying psychiatric disorder.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Importance Of Assessing the Impact Of Tdmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations

Jackson¹,

Brams²,

Citrome³

et al. 2021

NDT

View full text Add to dashboard Cite

show abstract

“…The reputed anosognosia of patients about TD and its lack of impact on quality of life have been called into question. In an online survey of a selected sample of patients with various psychiatric diagnoses, 2 TD subjects had worse figures for health-related quality-of-life scores and social withdrawal than those without TD, and this was particularly true of those with schizophrenia, a surprising finding given that approximately 50% of subjects with schizophrenia have apparently no or low awareness of TD. 3 In a cohort of 204 patients living with a schizophrenia spectrum disorder (54%) or another psychiatric condition and TD, over 40% reported that their involuntary movements had at least some impact on their quality of life, and three-quarters felt self-conscious or embarrassed about these movements.…”

Section: Epidemiology and Functional Impairmentmentioning

confidence: 96%

A Focused Update on Tardive Dyskinesia

Blanchet

2020

Can. J. Neurol. Sci.

View full text Add to dashboard Cite

Tardive dyskinesia (TD) is a delayed and potentially irreversible motor complication following chronic exposure to centrally acting dopamine receptor antagonists, mainly of the class of antipsychotics drugs. New generations of antipsychotic drugs reduced its mean prevalence to 20%, but it continues to mar the drug experience and social integration in a significant fraction of patients. The underlying molecular cascade remains elusive, explaining in part why TD management is so often difficult. Protocol variations between experimental laboratories and inter-species differences in the biological response to antipsychotic drugs have added layers of complexity. The traditional dopamine D2 receptor supersensitivity hypothesis was revisited in an experimental nonhuman primate model. Findings in the striatum revealed a strong upregulation of D3, not D2, receptors specific to dyskinetic animals, and indirect evidence suggestive of a link between overactivation of glycogen synthase kinase-3β signaling and TD. New effective vesicular monoamine transporter type 2 inhibitors alleviating TD have been approved in the USA. They were integrated to an emerging stepwise treatment algorithm for troublesome TD, which also includes consideration for changes in the current antipsychotic drug regimen and recognition of potentially aggravating factors such as anticholinergic co-medications. These advances may benefit TD.

show abstract

“…2 In addition to the physical symptoms experienced by patients, TD can also have a prominent effect on emotional and mental well-being. 3 This is evident in a 2019 study that reported patients with TD typically have a significantly lower quality of life. The effect of TD on a patient's quality of life was further emphasized by data correlating more severe TD symptoms with a lower clinician and self-reported quality of life.…”

Section: Introductionmentioning

confidence: 98%

Valbenazine for the Treatment of Adults with Tardive Dyskinesia

Gupta

Moity

Jumonville

et al. 2021

Health Psychology Research

View full text Add to dashboard Cite

This a comprehensive review of the literature regarding the use of Valbenazine in treating tardive dyskinesia. A primarily oral movement disorder induced by chronic exposure to certain classes of medications, tardive dyskinesia is often resistant to many therapeutic approaches. This review presents the background, evidence, and indications for the use of Valbenazine as a treatment option for this condition. Recent FindingsTardive dyskinesia is a disorder arising from long-term exposure to medications that blocked dopamine receptors, primarily antipsychotics. It is characterized by abnormal movements of the oral-buccal-lingual structures as well as associated pain and hypertrophy. Simply stopping the use of the dopamine blocking agents effectively alleviates the symptoms but is not always reliable hence the need for another therapeutic approach.Valbenazine is thought to function as a highly selective inhibitor of the VMAT2 vesicular monoamine transporter resulting in decreased availability of dopamine in the presynaptic cleft. This leads to decreased dopaminergic activation of the striatal motor pathway. The FDA approved Valbenazine in 2017 to treat tardive dyskinesia in adults and needs to be evaluated with existing therapeutic approaches.

show abstract

Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia

Cited by 37 publications

References 15 publications

Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations

Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations

A Focused Update on Tardive Dyskinesia

Valbenazine for the Treatment of Adults with Tardive Dyskinesia

Contact Info

Product

Resources

About